Symrise invests in Cellibre, a U.S.-based biotechnology company, to accelerate innovation for taste balancing and cosmetic actives markets

Symrise announced a strategic equity investment in Cellibre, a U.S.-based biotechnology company specialising in sustainable biomanufacturing. This partnership positions Symrise at the forefront of fermentation-derived ingredients that are better for both people and planet. It will initially focus on innovation across taste solutions and cosmetic actives, reinforcing its long-term competitiveness and sustainability leadership.

By partnering with Cellibre, Symrise gains preferred access to proprietary, fermentation-based technology, enabling scalable production of high-value ingredients across food, beverage, cosmetics, and nutraceutical sectors. With this investment, Symrise will leverage Cellibre’s world-class biotechnology platform to enable a more resilient supply chain, mitigating seasonal and cultivation variability.

Cellibre brings a significant track record in designing and engineering microorganisms for the production of cultured natural products and chemicals that are utilised in pharmaceuticals, functional health, beauty ingredients, industrial applications, and more.

This collaboration supports Symrise’s ambition to integrate biotechnology across its operations, ensuring long-term resilience, portfolio diversification, and competitive advantage. It also aligns with the company’s sustainability commitments and consumer-driven innovation strategy.